Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pediatrix Medical (MD) Shares Outstanding (Weighted Average) (2016 - 2025)

Pediatrix Medical (MD) has disclosed Shares Outstanding (Weighted Average) for 9 consecutive years, with $84.5 million as the latest value for Q1 2021.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 2.09% to $84.5 million in Q1 2021 year-over-year; TTM through Mar 2021 was $84.5 million, a 2.09% increase, with the full-year FY2020 number at $83.4 million, up 0.97% from a year prior.
  • Shares Outstanding (Weighted Average) was $84.5 million for Q1 2021 at Pediatrix Medical, up from $83.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $93.0 million in Q2 2018 to a low of $82.4 million in Q3 2019.
  • A 5-year average of $86.6 million and a median of $84.2 million in 2020 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): decreased 10.49% in 2019, then increased 2.09% in 2021.
  • Pediatrix Medical's Shares Outstanding (Weighted Average) stood at $92.4 million in 2017, then dropped by 1.44% to $91.1 million in 2018, then decreased by 9.34% to $82.6 million in 2019, then grew by 0.97% to $83.4 million in 2020, then increased by 1.36% to $84.5 million in 2021.
  • Per Business Quant, the three most recent readings for MD's Shares Outstanding (Weighted Average) are $84.5 million (Q1 2021), $83.4 million (Q4 2020), and $83.9 million (Q3 2020).